Hjem › Kronisk lymfatisk leukemi › New York
Kliniske studier for Kronisk lymfatisk leukemi i New York
26 studier for Kronisk lymfatisk leukemi søker deltakere på steder i New York.
Byer i New York
Offisiell studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster
RekruttererFase 3
Alder 65 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
- Roswell Park Cancer Institute, Buffalo
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, New York
- Research Site, New York
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Hematology Oncology Associates of CNY at Camillus, Camillus
- Memorial Sloan Kettering Commack, Commack
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse
- og 10 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Memorial Sloan Kettering Cancer Center Mskcc, New York
- Optum Medical Care, Pc, Westbury
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Roswell Park Comprehensive Cancer Center, Buffalo
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- og 1 flere
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Columbia University Medical Center, New York
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Memorial Sloan Kettering Cancer Center Mskcc, New York
- New York Cancer and Blood Specialists, Shirley
- Optum Medical Care, Pc, Westbury
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- New York Oncology Hematology, P.C. ( Site 5453), Albany
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- New York Oncology Hematology, P.C. ( Site 0069), Albany
- Roswell Park Cancer Institute ( Site 0023), Buffalo
- RPCI Oncology, PC- Northtowns ( Site 0061), Williamsville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Cayuga Cancer Center, Ithaca
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- David H. Koch Center for Cancer Care, New York
- Montefiore Medical Center PRIME, The Bronx
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, New York
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06564038Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT03666000Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
- Memorial Sloan Kettering Cancer Center, New York
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06849713Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
- University of Rochester NCORP Research Base, Rochester
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jun. 2026 · NCT07638007A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Icahn School of Medicine at Mount Sinai /ID# 266328, New York
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. apr. 2026 · NCT06428019Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT07218510A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Northwell Health, Lake Success
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Cayuga Cancer Center, Ithaca
- Northwell Health, Lake Success
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
- og 2 flere
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Roswell Park Comprehensive Cancer Center, Buffalo
- Weill Cornell, New York
- Montefiore Medical Center, The Bronx
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Optum Medical Care PC, Westbury
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. des. 2025 · NCT05602363Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
- Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2025 · NCT05643235Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.